Sex Differences in Immune Response During Acute Febrile Illness

Abstract

Sex-based differences in immune response are increasingly recognized as crucial determinants of clinical outcomes during acute febrile illnesses. This review synthesizes current evidence on the epidemiological trends, immunological mechanisms, risk factors, clinical presentations, diagnostic considerations, management strategies, and guideline recommendations with a focus on sex-specific implications. By examining recent advances and emerging therapies, this article aims to inform clinicians about the practical significance of understanding sex differences in the context of acute febrile illness and foster an individualized approach to patient care.

Introduction

Acute febrile illnesses (AFIs) are among the most common reasons for medical consultations globally, encompassing a spectrum of infectious etiologies such as viral, bacterial, and parasitic pathogens. While fever is a universal physiological response, emerging data highlight that sex differences—rooted in genetic, hormonal, and immunological factors—significantly influence the course and severity of AFIs. Understanding these differences is vital for optimizing clinical outcomes, tailoring therapeutic interventions, and improving prognostic accuracy for both male and female patients.

Epidemiology / Disease Burden

The incidence and severity of AFIs exhibit marked sex-based variations across different age groups and geographic regions. Data from large epidemiological studies indicate that males generally have a higher incidence of certain bacterial infections, whereas females show increased susceptibility to viral pathogens such as influenza and dengue. These differences are further modulated by age, with prepubertal children showing fewer distinctions, while pronounced disparities emerge post-puberty and during reproductive years, influenced largely by hormonal milieus. Notably, mortality and hospitalization rates for acute infections like sepsis and pneumonia are often higher in men, while women may experience more pronounced immune-mediated complications.

Pathophysiology

Sexual dimorphism in immune function is primarily driven by genetic and hormonal influences. The X chromosome, harboring numerous immune-related genes, confers females with a more robust innate and adaptive immune response. Estrogens enhance antibody production, upregulate Toll-like receptor expression, and promote pro-inflammatory cytokine release, while androgens such as testosterone generally exert immunosuppressive effects. This results in females often mounting a stronger initial response to pathogens but also a higher risk of immune-mediated tissue damage. Conversely, males may experience a delayed and less vigorous immune activation, predisposing them to more severe infections but fewer autoimmune sequelae. Additionally, recent research implicates sex-specific epigenetic modifications and microbiome differences as contributors to these divergent responses.

Risk Factors

Several risk factors for adverse outcomes in AFIs demonstrate sex-related variability. Comorbidities such as diabetes, cardiovascular disease, and obesity disproportionately affect men, augmenting their risk of severe infection. In women, pregnancy introduces unique immunological adaptations that can exacerbate or ameliorate the course of certain AFIs. Lifestyle factors—including smoking, alcohol consumption, and occupational exposures—also display distinct gender patterns, further influencing susceptibility and disease trajectory. Genetic polymorphisms in immune-regulatory genes, variably expressed between sexes, add an additional layer of risk stratification.

Clinical Features

Clinical manifestations of AFIs can differ between men and women. Females often report more pronounced constitutional symptoms such as fatigue, myalgias, and arthralgias, which may reflect heightened immune activation. Males, on the other hand, are more likely to present with fulminant infection, rapid progression to sepsis, or organ dysfunction. Sex-based disparities in symptom reporting and healthcare-seeking behavior may further complicate timely diagnosis and intervention. Notably, certain complications, such as cytokine storm syndromes in viral infections, are observed with higher frequency in females, whereas secondary bacterial infections are more prevalent among males.

Diagnosis

Diagnostic evaluation of AFIs requires consideration of sex-specific baseline laboratory values and immune response profiles. Females may exhibit higher levels of circulating immunoglobulins and acute-phase reactants, potentially confounding the interpretation of inflammatory markers. Sex hormones can affect leukocyte counts and cytokine profiles, necessitating age- and sex-adjusted reference ranges. Diagnostic algorithms should incorporate awareness of atypical presentations and complications more common in either sex. Point-of-care molecular diagnostics and biomarker panels are under investigation for their utility in refining sex-specific diagnostic accuracy.

Treatment & Management

Management strategies for AFIs should be individualized with recognition of sex-based pharmacokinetic and pharmacodynamic differences. Females often metabolize certain antibiotics and antivirals differently, influencing both efficacy and risk of adverse effects. Immunomodulatory therapies, such as corticosteroids or biologics, may require dose adjustments and vigilant monitoring for sex-specific side effects. Supportive care, including fluid management and organ support, should account for physiological differences in cardiac and renal function. Addressing social determinants of health, such as access to care and gender-based disparities, remains a critical component of comprehensive management.

Recent Advances / Emerging Therapies

Recent advances in immunogenomics and precision medicine are shedding light on novel therapeutic targets tailored to sex-specific immune pathways. Clinical trials of monoclonal antibodies, cytokine inhibitors, and vaccine adjuvants are increasingly stratifying outcomes by sex, revealing differential efficacy and safety profiles. Adoptive cell therapies and personalized immunotherapies are on the horizon, offering promise for optimizing immune modulation in both men and women. Ongoing research into the role of sex hormones and hormone replacement therapy in modulating acute immune responses may further refine future therapeutic strategies.

Guideline Recommendations

Major clinical guidelines now acknowledge the importance of sex as a biological variable in the management of infectious diseases. Recommendations emphasize sex-specific risk stratification for complications, tailored dosing of select pharmacological agents, and heightened surveillance for immune-mediated adverse events in women. There is a growing advocacy for inclusion of sex-stratified data in clinical research, fostering an evidence base that supports individualized patient care. Education of healthcare professionals on the clinical relevance of sex differences is paramount to bridging the gap between research and practice.

Conclusion

Recognition of sex differences in immune response during acute febrile illness is pivotal for advancing patient-centered care. Integrating knowledge of epidemiological trends, immunological mechanisms, and clinical implications into practice enhances diagnostic accuracy, optimizes therapeutic interventions, and improves outcomes for both male and female patients. Continued research and guideline development are essential to fully harness the benefits of sex-specific medicine in the management of acute febrile illnesses.